Reply AI Film Festival - Announced the Winners of the First International Festival for Short Films Made With Artificial Intelligence
4.9.2024 10:30:00 EEST | Business Wire | Press release
The winners of the first edition of the Reply AI Film Festival have been announced, the competition for authors of original short films made with Artificial Intelligence (AI), conceived by Reply, a leading international group in the creation of new business models enabled by AI and Digital Media. The awards event, organized in collaboration with Mastercard, was held at the Priceless lounge of the Hotel Excelsior in Venice.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240904521664/en/
Reply presents the inaugural Reply AI Film Festival, an international competition where Artificial Intelligence (AI) serves not only as a catalyst for innovation in the realm of creative storytelling but also as a tool for fostering inclusivity among younger generations in video and film production. (Photo: Business Wire)
The award for Best Short Film was given to 'To Dear Me' byGisele Tong, which tells the story of a young woman, tormented by memories of her parents' divorce and her mother's loneliness, struggling with love, feeling lost and distrustful, until she realizes that finding her true self is the key to healing and moving forward.
Second place went to 'One Way' byEgor Kharlamov, a story about how life can offer a second chance even when it seems there's nothing left to lose. The film ponders on what the price of this second opportunity is.
Third place was awarded to 'Jinx' byMansha Totla, thatfocuses on the memories of World War II through the voice of the main character, Jinx Akerkar, and emphasizes on the fragility of life. An intense dedication to those who lost their lives during the war and those who are still affected by that loss today.
The three winning short films were built around the theme "Synthetic Stories, Human Hearts" and were selected from the twelve finalists by an international jury, which was composed of Adam Kulick, Caleb & Shelby Ward, Denise Negri, Filippo Rizzante, Flavio Natalia, Julien Vallée & Eve Duhamel, Monica Riccioni, Paul Trillo, and Rob Minkoff.
To identify the finalists, the jurors reviewed over 1,000 short films submitted from more than 59 countries, including the USA, UK, Italy, Germany, Spain, France, Brazil, China, India, and Korea. AI artists, directors, writers, animators, VFX artists, but also amateurs were in the talent pool who were competing in the contest, preferring the Narratives and Experimental categories, chosen respectively by 38% and 36% of participants - followed by Documentary (14%) and Pilots (12%).
“To Dear Me, inspired by the animated short film Liebestraum by Yan Xiaoxuan, is a letter written by the creative team to girls and women everywhere. The story condenses the experiences of the many girls and women around them - their mothers, friends, and students. Many of these women carry the scars and flaws of their upbringing, lacking love, yearning for love, but unsure how to love. They often swing between love and hatred, desperately trying to hold onto anyone who loves them, investing all their emotions until they get hurt and become afraid to open their hearts again. They can even lose themselves in a web of false pretenses, doubting if they will ever find true love or even retain the ability to express it properly. With this short film, I want to tell these tender souls around me that even if we lose the love of the world, we must still love ourselves. I encourage them to take a good look at their own lives - the good and the bad - as these precious experiences have shaped each of us into the unique individuals we are. Rescue your past self and empower your present self. My dear girls, it has not been easy on this journey of growth, but remember to love yourselves well and give yourselves a warm embrace,” commented Gisele Tong, who was awarded first place in the competition.
“We are very happy to be part of the festival! This is a great honor and joy for us! Technology is moving forward and the fact that today there is such an opportunity to use artificial intelligence as a tool in the creation of movies and animation, is an incredible breakthrough. A story in a movie can now be told by anyone, that's great! It is important to remember that any technology is a tool in the hands of man, an incredibly powerful tool and let it serve for the benefit of mankind. Thank you to the festival for highlighting the first steps of new opportunities!” commented Egor Kharlamov, the second-place winner.
“The Reply AI Film Festival has been an incredible experience and I’m so happy that my film, ‘JINX’ was selected as a finalist. The festival team has been so attentive and the appreciation of my work has motivated me to further believe in myself. I was stuck for the past 3 years as I didn’t simply want to fill in the gaps of my film with random stock footage of the war. Thus, the most significant thing about my film was the use of AI to create WW2 footage that is authentic to my subject’s story. I believe that in the future, AI will transform the filmmaking industry and it’ll be interesting to see how we incorporate AI's capabilities with our human vision and artistic intuition,” commented Mansha Totla, the third-place winner.
“The winners of the Reply AI Film Festival demonstrate how Artificial Intelligence enables the creation of new narratives, innovative, and visually captivating content, while maintaining the essential human element—the vision, heart, and soul of a film,” said Filippo Rizzante, CTO of Reply. “The Reply AI Film Festival has become an important opportunity to highlight innovation and creativity, offering young talent the chance to immerse themselves in new technologies, acquire advanced skills, and create new, more accessible and sustainable creative scenarios.”
“We are pleased to have hosted in Venice the awards event of the Reply AI Film Festival, a competition that enhances the creativity of young film talents, offering them a unique opportunity for interaction and expression,” said Luca Fiumarella, Head of Marketing Italy at Mastercard. “We are committed to promoting initiatives where technology combines with great passions, creating new opportunities to bring people closer to the world of art and cinema. Our goal is to make artistic production more accessible and inclusive, using technological innovation to fuel creativity and support new generations in pursuing their aspirations.”
The Reply AI Film Festival was created by Reply as part of its program to promote new technologies among younger generations. The goal is to foster a culture of innovation and provide a new, stimulating space for experimentation, offering a space where AI can be put to the test as an ally of human creativity and demonstrate that the synergy between people and technologies can enable new scenarios that are more accessible to anyone who possesses the spark of creativity. The competition is part of the Reply Challenges, a program of technological and creative competitions that testify to Reply's commitment to developing innovative educational models capable of engaging new generations. Today Reply's Challenges have a community of more than 150,000 participants.
To see the winning short films and finalists, visit aiff.reply.com.
Reply
Reply [EXM, STAR: REY] specialises in the design and implementation of solutions based on new communication channels and digital media. Reply is a network of highly specialised companies supporting key European industrial groups operating in the telecom and media, industry and services, banking, insurance and public administration sectors in the definition and development of business models enabled for the new paradigms of big data, cloud computing, digital media and the Internet of Things. Reply services include: Consulting, System Integration and Digital Services. www.reply.com
Mastercard
Mastercard is an international payments technology company. Our goal is to create connections and promote an inclusive digital economy from which everyone can benefit, wherever they are, through secure, simple, fast and accessible transactions. By being able to rely on secure data and networks, partnerships and passion, and our products and solutions, we help consumers, financial institutions, governments and businesses reach their full potential. With a presence in more than 210 countries and territories, we are building a more sustainable world that offers priceless opportunities for all. www.mastercard.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240904521664/en/
Contacts
Reply
Fabio Zappelli
f.zappelli@reply.com
Irene Caia
i.caia@reply.com
Mastercard
Giuliana Abbate
E. Giuliana.Abbate@mastercard.com
Omnicom PR Group
Ufficio Stampa Mastercard
T. 02 6241 19
E. mln.mastercard@fleishmaneurope.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 15:32:00 EEST | Press release
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company's plans to advance the program globally. The FDA granted RPD Designation based on its determination that A-T is a serious and life-threatening disease that primarily affects individ
Esri Introduces ArcGIS Velocity for ArcGIS Enterprise to Power Real-Time GIS Operations13.7.2026 15:00:00 EEST | Press release
Esri, the global leader in location intelligence, has released for general availability ArcGIS Velocity for ArcGIS Enterprise for self-hosted deployments on Windows and Linux. This enables organizations to leverage Velocity from secure on-premises and private cloud environments. Available as software as a service (SaaS) for ArcGIS Online and now for self-hosted environments in ArcGIS Enterprise, Esri’s next-generation geospatial capability delivers real-time analytics on streaming, Internet of Things (IoT), sensor, and asset data. It helps organizations track and visualize public events, supply chains, and infrastructure to identify and respond to potential threats. ArcGIS Velocity for ArcGIS Enterprise expands cloud-native support to enterprise customers across industries in government and business that rely on firewall protection and internal security compliance. ArcGIS Velocity connects to more than 20 ready-to-use feeds for real-time data providers, including Dataminr, Samsara, Fli
HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization of the Edison® Histotripsy Platform13.7.2026 15:00:00 EEST | Press release
HistoSonics, today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713505048/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image guided platform that is intended for the destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors. It uses the mechanical properties of focused ultrasound, called histotripsy, to liquefy and destroy unwanted tissue and tumors in a single procedure without the need for invasive procedures or radiation, and with potentially fewer side effects than traditional therapies. CE Mark approval follows an increasing number of regulatory clearances and was supported by a growing body of clinical ev
SLB OneSubsea Awarded EPC Contract for Eni’s Baleine Phase 3 Project Offshore Côte d'Ivoire13.7.2026 15:00:00 EEST | Press release
Global energy technology company SLB (NYSE: SLB) announced today that its OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260712734539/en/ SLB OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. Under the contract, SLB OneSubsea will deliver complete subsea production systems (SPS) for 13 wells, reinforcing its role as a core technology and execution partner on one of the most strategically significant offshore developments currently underway in the region. The EPC scope includes subsea trees, umbilical, manifolds, multiphase flowmeters and control systems, along with installation, commissionin
Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer13.7.2026 13:00:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that it has entered into a securities purchase agreement for a private placement of approximately $85 million in upfront gross proceeds, before the deduction of private placement expenses, and up to an additional $255 million upon the full exercise of purchase warrants. The financing was led by Commodore Capital, with participation from RA Capital Management, TCGX, Invus, and Ligand Pharmaceuticals. The net proceeds of this financing are expected to support Agenus’ strategic prioritization of botensilimab and balstilimab (BOT+BAL) for the neoadjuvant treatment of microsatellite-stable (MSS) colon cancer, including advancement of ROBBIN1, the Company’s planned registrational Phase 3 neoadjuvant trial in microsatellite-stable (MSS) colon cancer. High-risk Stage II and Stage III MSS colon cancer affect an estimated 38,000 patients annually in the US and more than 200,000 patients worldwide,2 representing a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom